Nanomedicine for the Brain and the Eye: Disease Management in Poorly Accessible Compartments of the Body

Handbook of Nanotoxicology, Nanomedicine and Stem Cell Use in Toxicology

Volumn , Issue , 2014, Pages 223-248

  Cattaneo, Anna G ^a   Gornati, Rosalba ^a,b   Bernardini, Giovanni ^a,b   Sabbioni, Enrico ^c   Manzo, Luigi ^d   Di Gioacchino, Mario ^e  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b The Protein Factory University Center for Protein Biotechnology   (Italy)

^c ECSIN European Center for the Sustainable Impact of Nanotechnology   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

Blood brain barrier; Blood retinal barrier; Central nervous system diseases; Hydrogels; Nanomaterials; Posterior pole diseases

Indexed keywords

BLOOD; CONTROLLED DRUG DELIVERY; HYDROGELS; IRON OXIDES; MAGNETIC RESONANCE IMAGING; MEDICAL NANOTECHNOLOGY; NANOMAGNETICS; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NEUROPHYSIOLOGY; SOL-GELS; TARGETED DRUG DELIVERY;

BLOOD-BRAIN BARRIER; BLOOD-RETINAL BARRIER; CENTRAL NERVOUS SYSTEMS; DISEASE MANAGEMENT; EXTERNAL MAGNETIC FIELD; IRON OXIDE NANOPARTICLE; PHARMACOLOGICAL TREATMENT; SOL-GEL PHASE TRANSITION;

DIAGNOSIS;

EID: 84933540315     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118856017.ch13     Document Type: Chapter

References (210)

1. Addae C, Yi X, Gernapudi R, Cheng H, Musto A, Martinez-Ceballos E. 2012. All-trans-retinoid acid induces the differentiation of encapsulated mouse embryonic stem cells into GABAergic neurons. Differentiation 83(5): 233-241. doi: 10.1016/j.diff.2012.03.001.
2. Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knöbl P, Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jäger U, Valent P. 2007. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur. J. Clin. Invest. 37(10): 808-813.
3. Akiyama G, Sakai T, Kuno N, Kimura E, Okano K, Kohno H, Tsuneoka H. 2012. Photoreceptor rescue of pigment epithelium-derived factor-impregnated nanoparticles in Royal College of Surgeons rats. Mol. Vis. 18: 3079-3086.
4. Albrecht KW, deWitt Hamer PC, Leenstra S, Bakker PJ, Beijnen JH, Troost D, Kaaijk P, Bosch AD. 2001. High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin. J. Neurooncol. 53(3): 267-271.
5. Ananda S, Nowak AK, Cher L, Dowling A, Brown C, Simes J, Rosenthal MA, Cooperative Trials Group for Neuro-Oncology (COGNO). 2011. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J. Clin. Neurosci. 18(11): 1444-1448. doi: 10.1016/j.jocn.2011.02.026.
6. Ananthanarayanan B, Kim Y, Kumar S. 2011. Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 32(31): 7913-7923. doi: 10.1016/j.biomaterials.2011.07.005.
7. Aoki H, Kakinuma K, Morita K, Kato M, Uzuka T, Igor G, Takahashi H, Tanaka R. 2004. Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int. J. Hyperthermia 20(6): 595-605.
8. Araújo J, Nikoli S, Egea MA, Souto EB, Garcia ML. 2011. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Coll. Surf. B Biointerf. 88: 150-157.
9. Araújo J, Garcia ML, Mallandrich M, Souto EB, Calpena AC. 2012. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine 8(6): 1034-1041. doi: 10.1016/j.nano.2011.10.015.
10. Arosarena O, Guerin C, Brem H, Laterra J. 1994. Endothelial differentiation in intracerebral and subcutaneous experimental gliomas. Brain Res. 640(1-2): 98-104.
11. Arthur AS, Wilson SA, Dixit S, Barr JD. 2005. Hydrogel-coated coils for the treatment of cerebral aneurysms: preliminary results. Neurosurg. Focus 18(2): E1. doi: 10.3171/foc.2005.18.2.2.
12. Baehr C, Reichel V, Fricker G. 2006. Choroid plexus epithelial monolayers-a cell culture model from porcine brain. Cerebrospinal Fluid Res. 3: 13. doi: 10.1186/1743-8454-3-13.
13. Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer O, Steinbrecher A, Hirschmann B, Brawanski A, Dietmaier C, Jauch-Worley T, Kölbl O, Pietsch T, Proescholdt M, Rümmele P, Muigg A, Stockhammer G, Hegi M, Bogdahn U, Hau P. 2009. RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma-a phase II study. BMC Cancer 9: 308. doi: 10.1186/1471-2407-9-308.
14. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV. 2012. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485: 512-516. doi: 10.1038/nature11087.
15. Benesch M, Siegler N, Kv H, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C. 2009. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs 20(9): 794-799. doi: 10.1097/CAD.0b013e32832f4abe.
16. Boddu SH, Jwala J, Vaishya R, Earla R, Karla PK, Pal D, Mitra AK. 2010. Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. J. Ocul. Pharmacol. Ther. 26(1): 37-48. doi: 10.1089/jop.2009.0074.
17. Boiardi A, Pozzi A, Salmaggi A, Eoli M, Zucchetti M, Silvani A. 1999. Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. Cancer Chemother. Pharmacol. 43(2): 178-179.
18. Boiardi A, Eoli M, Salmaggi A, Lamperti E, Botturi A, Broggi G, Bartolomei M, Silvani A. 2003. New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM). J. Exp. Clin. Cancer Res. 22(4 Suppl): 123-127.
19. Boiardi A, Eoli M, Salmaggi A, Lamperti E, Botturi A, Solari A, Di Meco F, Broggi G, Silvani A. 2005. Local drug delivery in recurrent malignant gliomas. Neurologic. Sci. 26(Suppl 1): S37-S39.
20. Boyes WK, Chen R, Chen C, Yokel RA. 2012. The neurotoxic potential of engineered nanomaterials. Neurotoxicology 33(4): 902-910. doi: 10.1016/j.neuro.2011.12.013.
21. Brun E, Carrière M, Mabondzo A. 2012. In vitro evidence of dysregulation of blood-brain barrier function after acute and repeated/long-term exposure to TiO2 nanoparticles. Biomaterials 33: 886-896. doi: 10.1016/j.biomaterials.2011.10.025.
22. Cabane E, Zhang X, Langowska K, Palivan CG, Meier W. 2012. Stimuli-responsive polymers and their applications in nanomedicine. Biointerphases 7(1-4): 9. doi: 10.1007/s13758-011-0009-3.
23. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI. 2009. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One 4(4): e5290. doi: 10.1371/journal.pone.0005290.
24. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. 2008. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch. Ophthalmol. 126(9): 1191-1201. doi: 10.1001/archopht.126.9.1191.
25. Campochiaro PA. 2000. Retinal and choroidal neovascularization. J. Cell. Phys. 184(3): 301-310. doi: 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H.
26. Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, Abbruzzese A, Palmieri G, Budillon A, Grillone F, Venuta S, Tagliaferri P, Del Prete S. 2006. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother. Pharmacol. 57(1): 34-39.
27. Carmeliet P, De Stooper B. 2012. Alzheimer's disease: a breach in the blood-brain barrier. Nature 485: 451-452.
28. Chamberlain MC. 2012. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J. Neurooncol. 109(1): 143-148. doi: 10.1007/s11060-012-0880-x.
29. Chamberlain MC, Glantz MJ. 2005. Cerebrospinal fluid-disseminated meningioma. Cancer 103(7): 1427-1430.
30. Chang J, Paillard A, Passirani C, Morille M, Benoit J-P, Betbeder D, Garcion E. 2012. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm. Res. 29: 1495-1505. doi: 10.1007/s11095-011-0624-1.
31. Chao KH, Riina HA, Heier L, Steig PE, Gobin YP. 2004. Endovascular management of dolichoectasia of the posterior cerebral artery report. AJNR Am. J. Neuroradiol. 25(10): 1790-1791.
32. Chen KS, Mitchell DA. 2012. Monoclonal antibody therapy for malignant glioma. Adv. Exp. Med. Biol. 746: 121-141. doi: 10.1007/978-1-4614-3146-6_10.
33. Chen J, Patil S, Seal S, McGinnis JF. 2006. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat. Nanotechnol. 1(2): 142-150. doi: 10.1038/nnano.2006.91.
34. Chen L, Zhang B, Toborek M. 2013. Autophagy is involved in nanoalumina-induced cerebrovascular toxicity. Nanomed. Nanotechnol. Biol. Med. 9(2): 212-221. doi: 10.1016/j.nano.2012.05.017.
35. Cheng KT. 2007. Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody. In Molecular Imaging and Contrast Agent Database (MICAD). [Internet] National Center for Biotechnology Information (US): Bethesda, MD, 2004-2013. http://www.ncbi.nlm.nih.gov/books/NBK23268/ (accessed 12 July 2013).
36. Cheng L, Anglin E, Cunin F, Kim D, Sailor MJ, Falkenstein I, Tammewar A, Freeman WR. 2008. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle. Br. J. Ophthalmol. 92(5): 705-711. doi: 10.1136/bjo.2007.133587.
37. Chi YM, Wang YT, Wang Y, Maier C, Jung TP, Cauwenberghs G. 2012. Dry and noncontact EEG sensors for mobile brain-computer interfaces. IEEE Trans. Neural Syst. Rehabil. Eng. 20(2): 228-235. doi: 10.1109/TNSRE.2011.2174652.
38. Chikar JA, Hendricks JL, Richardson-Burns SM, Raphael Y, Pfingst BE, Martin DC. 2012. The use of a dual PEDOT and RGD-functionalized alginate hydrogel coating to provide sustained drug delivery and improved cochlear implant function. Biomaterials 33(7): 1982-1990. doi: 10.1016/j.biomaterials.2011.11.052.
39. Chua SL, Rosenthal MA, Wong SS, Ashley DM, Woods AM, Dowling A, Cher LM. 2004. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol. 6(1): 38-43.
40. Conova L, Vernengo J, Jin Y, Himes BT, Neuhuber B, Fischer I, Lowman A, Vernengo J, Jin Y, Himes BT, Neuhuber B, Fischer I, Lowman A. 2011. A pilot study of poly(N-isopropylacrylamide)-g-polyethylene glycol and poly(N-isopropylacrylamide)-g-methylcellulose branched copolymers as injectable scaffolds for local delivery of neurotrophins and cellular transplants into the injured spinal cord. J. Neurosurg. Spine 15(6): 594-604. doi: 10.3171/2011.7.SPINE11194.
41. Dallacasagrande V, Zink M, Huth S, Jakob A, Müller M, Reichenbach A, Käs JA, Mayr SG. 2012. Tailoring substrates for long-term organotypic culture of adult neuronal tissue. Adv. Mater. 24(18): 2399-2403. doi: 10.1002/adma.201200816.
42. Dan M, Tseng MT, Wu P, Unrine JM, Grulke EA, Yokel RA. 2012. Brain microvascular endothelial cell association and distribution of a 5 nm ceria engineered nanomaterial. Int. J. Nanomedicine 7: 4023-4036.
43. Daneman R, Zhou L, Kebede AA, Barres BA. 2010. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468: 562-566.
44. De Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, Garcia E, Couvreur P. 2004. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 34(12): 3702-3712.
45. Del Pozo-Rodríguez A, Delgado D, Solinís MA, Gascón AR, Pedraz JL. 2008. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int. J. Pharmacol. 360(1-2): 177-183. doi: 10.1016/j.ijpharm.2008.04.023. 18508211.
46. Del Pozo-Rodríguez A, Delgado D, Gascón AR, Solinís MÁ. 2013. Lipid nanoparticles as drug/gene delivery systems to the retina. J. Ocul. Pharmacol. Ther. 29(2): 173-188. doi: 10.1089/jop.2012.0128.
47. Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, Kumada H, Sakurai Y, Masunaga S, Ono K, Miyatake S. 2008. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J. Neurooncol. 87(3): 287-294. doi: 10.1007/s11060-008-9522-8.
48. Dönmez H, Mavili E, Ikizceli T, Durak AC, Kurtsoy A. 2009. Stroke secondary to aseptic meningitis after endovascular treatment of a giant aneurysm with parent artery occlusion. Cardiovasc. Intervent. Radiol. 32(4): 801-803. doi: 10.1007/s00270-009-9504-z.
49. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG,WeberDA,Kuppermann BD, Csaky KG, Olsen TW,Kompella UB, Holers VM, Hageman GS, Gilger BC, Campochiaro PA, Whitcup SM, Wong WT. 2010. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest. Ophthalmol. Vis. Sci. 51(11): 5403-5420. doi: 10.1167/iovs.10-5392.
50. Egawa EY, Kato K, Hiraoka M, Nakaji-Hirabayashi T, Iwata H. 2011. Enhanced proliferation of neural stem cells in a collagen hydrogel incorporating engineered epidermal growth factor. Biomaterials 32(21): 4737-4743. doi: 10.1016/j.biomaterials.2011.03.033.
51. Emerich DF, Mooney DJ, Storrie H, Babu RS, Kordower JH. 2010a. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox. Res. 17(1): 66-74. doi: 10.1007/s12640-009-9079-0.
52. Emerich DF, Silva E, Ali O, Mooney D, Bell W, Yu SJ, Kaneko Y, Borlongan C. 2010b. Injectable VEGF hydrogels produce near complete neurological and anatomical protection following cerebral ischemia in rats. Cell Transplant. 19(9): 1063-1071. doi: 10.3727/096368910X498278.
53. Escuder-Gilabert L, Molero-Monfort M, Villanueva-Camañas RM, Sagrado S, Medina-Hernández MJ. 2004. Potential of biopartitioning micellar chromatography as an in vitro technique for predicting drug penetration across the blood-brain barrier. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 807(2): 193-201.
54. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, Steinbrecher A, Ullrich W, Bogdahn U. 2001. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92(7): 1936-1942.
55. Falchi L, Gunnellini M, Franco L, Ferrazza P, Ascani S, Liberati AM. 2010. Rapid and sustained response of an intra-and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy. J. Neurooncol. 97(1): 53-57. doi: 10.1007/s11060-009-9985-2.
56. Fiorillo A, Maggi G, Greco N, Migliorati R, D'Amico A, De Caro MD, Sabbatino MS, Buffardi F. 2004. Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors. J. Neurooncol. 66(2): 179-185.
57. Firth G, Oliver AS, McKeran RO. 1984. Studies on the use of antimitotic drugs entrapped within liposomes and of their action on a human glioma cell line. J. Neurologic. Sci. 63(2): 153-165.
58. Foreman SW, Thorngate L, Burr RL, Thomas KA. 2011. Electrode challenges in amplitude-integrated electroencephalography (aEEG): research application of a novel noninvasive measure of brain function in preterm infants. Biol. Res. Nurs. 13(3): 251-259. doi: 10.1177/1099800411403468.
59. Gaba RC, Ansari SA, Roy SS, Marden FA, Viana MA, Malisch TW. 2006. Embolization of intracranial aneurysms with hydrogel-coated coils versus inert platinum coils: effects on packing density, coil length and quantity, procedure performance, cost, length of hospital stay, and durability of therapy. Stroke 37(6): 1443-1450. doi: 10.1161/01.STR.0000221314.55144.0b.
60. Gao X, Qian J, Zheng S, Xiong Y, Man J, Cao B, Wang L, Ju S, Li C. 2013. Up-regulating blood brain barrier permeability of nanoparticles via multivalent effect. Pharm. Res. 30(10): 2538-2548. doi: 10.1007/s11095-013-1004-9.
61. Gaviani P, Silvani A, Corsini E, Erbetta A, Salmaggi A. 2009. Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report. Neurologic. Sci. 30(3): 251-254. doi: 10.1007/s10072-009-0044-8.
62. Georgieva JV, Brinkhuis RP, Stojanov K, Weijers CAGM, Zuilhof H, Rutjes FPJT, Hoekstra D, van Hest JCM, Zuhorn IS. 2012. Peptide-mediated blood-brain barrier transport of polymersome. Angew. Chem. Int. Ed. 51: 8339-88342. doi: 10.1002/anie.201202001.
63. Gil V, del Río JA. 2012. Analysis of axonal growth and cell migration in 3D hydrogel cultures of embryonic mouse CNS tissue. Nat. Protoc. 7(2): 268-280. doi: 10.1038/nprot.2011.445.
64. Glas M, Stuplich M, Tschampa H, Urbach H, Rasch K, Herrlinger U. 2008. Liposomal cytarabine given concomitantly with radiotherapy in a patient with leptomeningeal metastasis from breast cancer. J. Neurol. 255(11): 1838-1839. doi: 10.1007/s00415-008-0014-8.
65. Gok B, McGirt MJ, Sciubba DM, Garces-Ambrossi G, Nelson C, Noggle J, Bydon A, Witham TF, Wolinsky JP, Gokaslan ZL. 2009. Adjuvant treatment with locally delivered Onco-Gel delays the onset of paresis after surgical resection of experimental spinal column metastasis. Neurosurgery 65(1): 193-199. doi: 10.1227/01.NEU.0000345948.54008.82.
66. Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, Usner DW, Comstock TL. 2007. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch. Ophthalmol. 125(11): 1478-1485.
67. Grahn AY, Bankiewicz KS, Dugich-Djordjevic M, Bringas JR, Hadaczek P, Johnson GA, Eastman S, Luz M. 2009. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J. Neurooncol. 95(2): 185-197. doi: 10.1007/s11060-009-9917-1.
68. Groothuis DR. 2000. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2(1): 45-59.
69. Guo D, Bi H, Liu B, Wu Q, Wang D, Cui Y. 2013a. Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells. Toxicol. In Vitro 27(2): 731-738. doi: 10.1016/j.tiv.2012.12.001.
70. Guo D, Bi H, Wang D, Wu Q. 2013b. Zinc oxide nanoparticles decrease the expression and activity of plasma membrane calcium ATPase, disrupt the intracellular calcium homeostasis in rat retinal ganglion cells. Int. J. Biochem. Cell Biol. 45(8): 1849-1859. doi: 10.1016/j.biocel.2013.06.00210.1016/j.biocel.2013.06.002.
71. Haase SC, Chung KC. 2011. An evidence-based approach to treating thumb carpometacarpal joint arthritis. Plast. Reconstr. Surg. 127: 918-925.
72. Han Z, Conley SM, Makkia RS, Cooper MJ, Naash MI. 2012. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J. Clin. Invest. 122(9): 3221-3226. doi: 10.1172/JCI64833.
73. Hau P, Fabel K, Baumgart U, Rümmele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hübner F, Jauch T, Drechsel E, Kleiter I,Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J, Bogdahn U. 2004. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100(6): 1199-11207.
74. Hills BA. 1992. A hydrophobic oligolamellar lining to the vascular lumen in some organs. Undersea Biomed. Res. 19(2): 107-120.
75. Hoelting L, Scheinhardt B, Bondarenko O, Schildknecht S, Kapitza M, Tanavde V, Tan B, Lee QY, Mecking S, Leist M, Kadereit S. 2013. A 3-dimensional human embryonic stem cell (hESC)-derived model to detect developmental neurotoxicity of nanoparticles. Arch. Toxicol. 87(4): 721-733. doi: 10.1007/s00204-012-0984-2.
76. Hoffmann AL, Buhk JH, Strik H. 2009. Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. Anticancer Res. 29(12): 5191-5195.
77. Hosoya K, Tachikawa M. 2009. Inner blood-retinal barrier transporters: role of retinal drug delivery. Pharmacol. Res. 26(9): 2055-2065.
78. Huang GS, Juretzka M, Ciaravino G, Kohler S, Teng NN. 2002. Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. Gynecol. Oncol. 87(3): 313-318.
79. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. 2007. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109(8): 3214-3218.
80. Jayaraman MS, Bharali DJ, Sudha T, Mousa SA. 2012. Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration. Mol. Vis. 18: 2300-2308.
81. Jiang FX, Yurke B, Schloss RS, Firestein BL, Langrana NA. 2010. Effect of dynamic stiffness of the substrates on neurite outgrowth by using a DNA-crosslinked hydrogel. Tissue Eng. Part A 16(6): 1873-1889. doi: 10.1089/ten.TEA.2009.0574.
82. Jo DH, Kim JH, Yu YS, Lee TG, Kim JH. 2012. Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor. Nanomedicine 8(5): 784-791. doi: 10.1016/j.nano.2011.09.003.
83. Jurga M, Dainiak MB, Sarnowska A, Jablonska A, Tripathi A, Plieva FM, Savina IN, Strojek L, Jungvid H, Kumar A, Lukomska B, Domanska-Janik K, Forraz N, McGuckin CP. 2011. The performance of laminin-containing cryogel scaffolds in neural tissue regeneration. Biomaterials 32(13): 3423-3434. doi: 10.1016/j.biomaterials.2011.01.049.
84. Kai J, Nakamura K, Masuda T, Ueda I, Fujiwara H. 1996. Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography. J. Med. Chem. 39(13): 2621-2624.
85. Kaiser JM, Imai H, Haakenson JK, Brucklacher RM, Fox TE, Shanmugavelandy SS, Unrath KA, Pedersen MM, Dai P, Freeman WM, Bronson SK, Gardner TW, Kester M. 2012. Nanoliposomal minocycline for ocular drug delivery. Nanomedicine 9(1): 130-140. doi: 10.1016/j.nano.2012.03.004.
86. Kakinuma K, Tanaka R, Takahashi H,Watanabe M, Nakagawa T, Kuroki M. 1996. Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia. J. Neurosurg. 84(2): 180-184.
87. Kalishwaralal K, Barathmanikanth S, Pandian SR, Deepak V, Gurunathan S. 2010. Silver nano - a trove for retinal therapies. J. Control. Release 145(2): 76-90. doi: 10.1016/j.jconrel.2010.03.022.
88. Kasprowicz NS, Fotopoulou C, Oskay-Ozcelik G, El KK, Boehmer D, Sehouli J. 2008. Brain metastases in relapsed epithelial ovarian cancer after chemotherapy with pegylated liposomal doxorubicin. Anticancer Res. 28(3B): 1943-1946.
89. Kato T, Tsuchida T, Kawamoto K. 2005. Blood tumor permeability of experimental braintumor: an electron microscopic study using lanthanum. Neuropathology 25(1): 21-26.
90. Kato T, Natsume A, Toda H, Iwamizu H, Sugita T, Hachisu R, Watanabe R, Yuki K, Motomura K, Bankiewicz K, Wakabayashi T. 2010. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 17(11): 1363-1371. doi: 10.1038/gt.2010.88.
91. Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P, Dean B, Lee A, Borges S, Bouchard B, Tao W. 2012. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest. Ophthalmol. Vis. Sci. 53(12): 7484-7491. doi: 10.1167/iovs.12-9970.
92. Khaing ZZ, Milman BD, Vanscoy JE, Seidlits SK, Grill RJ, Schmidt CE. 2011. High molecular weight hyaluronic acid limits astrocyte activation and scar formation after spinal cord injury. J. Neural Eng. 8(4): 046033. doi: 10.1088/1741-2560/8/4/046033.
93. Khalifa A, Dodds D, Rampling R, Paterson J, Murray T. 1997. Liposomal distribution in malignant glioma: possibilities for therapy. Nucl. Med. Commun. 18(1): 17-23.
94. Khan W, Aldouby YH, Avramoff A, Domb AJ. 2012. Cyclosporin nanosphere formulation for ophthalmic administration. Int. J. Pharmacol. 437(1-2): 275-276. doi: 10.1016/j.ijpharm.2012.08.016.
95. Kim JH, Kim JH, Park JA, Lee SW, Kim WJ, Yu YS, Kim KW. 2006. Blood-neural barrier: intercellular communication at glio-vascular interface. J. Biochem. Mol. Biol. 39(4): 339-345.
96. Kim H, Robinson SB, Csaky KG. 2009. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm. Res. 26(2): 329-337. doi: 10.1007/s11095-008-9745-6.
97. Kim DH, Wiler JA, Anderson DJ, Kipke DR, Martin DC. 2010. Conducting polymers on hydrogel-coated neural electrode provide sensitive neural recordings in auditory cortex. Acta Biomater. 6(1): 57-62. doi: 10.1016/j.actbio.2009.07.034.
98. Kim JI, Kim B, Chun C, Lee SH, Song SC. 2012. MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection. Biomaterials 33(19): 4836-4842. doi: 10.1016/j.biomaterials.2012.03.048.
99. Kim KT, Zaikova T, Hutchison JE, Tanguay RL. 2013. Gold nanoparticles disrupt zebrafish eye development and pigmentation. Toxicol. Sci. 133(2): 275-288. doi: 10.1093/toxsci/kft081.
100. Klaassen I, Van Noorden CJ, Schlingemann RO. 2013. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog. Retin. Eye Res. 34: 19-48. doi: 10.1016/j.preteyeres.2013.02.001.
101. Kong SD, Lee I, Ramachandran S, Eliceiri BP, Shubayev VI, Lal R, Jin S. 2012. Magnetic targeting of nanoparticles across the intact blood-brain barrier. J. Control. Release 164: 49-57. doi: 10.1016/j.jconrel.2012.09.021.
102. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, Karkavitsas N. 2000. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer 83(10): 1281-1286.
103. Kremer S, Pinel S, Védrine PO, Bressenot A, Robert P, Bracard S, Plénat F. 2007. Ferumoxtran-10 enhancement in orthotopic xenograft models of human brain tumors: an indirect marker of tumor proliferation? J. Neurooncol. 83(2): 111-119.
104. Krol S, Macrez R, Docagne F, Defer G, Laurent S, Rahman M, Hajipour MJ, Kehoe PG, Mahmoudi M. 2013. Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. Chem. Rev. 113: 1877-1903. doi: 10.1021/cr200472g.
105. Lampe KJ, Mooney RG, Bjugstad KB, Mahoney MJ. 2010. Effect of macromer weight percent on neural cell growth in 2D and 3D nondegradable PEG hydrogel culture. J. Biomed. Mater. Res. A 94(4): 1162-1171. doi: 10.1002/jbm.a.32787.
106. Lampe KJ, Kern DS, Mahoney MJ, Bjugstad KB. 2011. The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: protein distribution and the glial response. J. Biomed. Mater. Res. A 96(3): 595-607. doi: 10.1002/jbm.a.33011.
107. Larsen KB, Lutterodt M, Rath MF, Møller M. 2009. Expression of the homeobox genes PAX6, OTX2, and OTX1 in the early human fetal retina. Int. J. Dev. Neurosci. 27(5): 485-492.
108. Lassaletta A, Perez-Olleros P, Scaglione C, Sirvent S, De Prada I, Perez-Martinez A, Ruiz-Hernandez A, Madero L. 2007. Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. J. Neurooncol. 83(3): 303-306.
109. Lee SJ, Sun J, Flint JJ, Guo S, Xie HK, King MA, Sarntinoranont M. 2011. Optically based-indentation technique for acute rat brain tissue slices and thin biomaterials. J. Biomed. Mater. Res. B Appl. Biomater. 97(1): 84-95. doi: 10.1002/jbm.b.31789.
110. Leipzig ND, Xu C, Zahir T, Shoichet MS. 2010. Functional immobilization of interferon-gamma induces neuronal differentiation of neural stem cells. J. Biomed. Mater. Res. A 93(2): 625-633. doi: 10.1002/jbm.a.32573.
111. Lessigiarska I, Pajeva I, Cronin MT, Worth AP. 2005. 3D QSAR investigation of the blood-brain barrier penetration of chemical compounds. SAR QSAR Environ. Res. 16(1-2): 79-91.
112. Li T, Zhang M, Han Y, Zhang H, Xu L, Xiang Y. 2010. Targeting therapy of choroidal neovascularization by use of polypeptideand PEDF-loaded immunoliposomes under ultrasound exposure. J. Huazhong Univ. Sci. Technol. 30(6): 798-803. doi: 10.1007/s11596-010-0661-8.
113. Li X, Liu X, Zhao W, Wen X, Zhang N. 2012. Manipulating neural-stem-cell mobilization and migration in vitro. Acta Biomater. 8(6): 2087-2095. doi: 10.1016/j.actbio.2012.02.008.
114. Li X, Liu X, Cui L, Brunson C, Zhao W, Bhat NR, Zhang N, Wen X. 2013. Engineering an in situ crosslinkable hydrogel for enhanced remyelination. FASEB J. 27(3): 1127-1136. doi: 10.1096/fj.12-211151.
115. Lim TC, Toh WS, Wang LS, Kurisawa M, Spector M. 2012. The effect of injectable gelatin-hydroxyphenylpropionic acid hydrogel matrices on the proliferation, migration, differentiation and oxidative stress resistance of adult neural stem cells. Biomaterials 33(12): 3446-3455. doi: 10.1016/j.biomaterials.2012.01.037.
116. Lim TC, Rokkappanavar S, Toh WS, Wang LS, Kurisawa M, Spector M. 2013. Chemotactic recruitment of adult neural progenitor cells into multifunctional hydrogels providing sustained SDF-1α release and compatible structural support. FASEB J. 27(3): 1023-1033. doi: 10.1096/fj.12-221515.
117. Ling Y, Wei K, Zou F, Zhong S. 2012. Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int. J. Pharm. 430(1-2): 266-275. doi: 10.1016/j.ijpharm.2012.03.047.
118. Lippens RJ. 1999. Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors. Pediatr. Hematol. Oncol. 16(2): 131-139.
119. Loch C, Zakelj S, Kristl A, Nagel S, Guthoff R, Weitschies W, Seidlitz A. 2012. Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes. Eur. J. Pharm. Sci. 47(1): 131-138. doi: 10.1016/j.ejps.2012.05.007.
120. Lu Y, Li Y, Pan J, Wei P, Liu N, Wu B, Cheng J, Lu C, Wang L. 2012a. Poly(3,4-ethylenedioxythiophene)/poly(styrenesulfonate)-poly(vinyl alcohol)/poly(acrylic acid) interpenetrating polymer networks for improving optrode-neural tissue interface in optogenetics. Biomaterials 33(2): 378-394. doi: 10.1016/j.biomaterials.2011.09.083.
121. Lu YJ, Yang HW, Hung SC, Huang CY, Li SM, Ma CC, Chen PY, Tsai HC, Wei KC, Chen JP. 2012b. Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide. Int. J. Nanomedicine 7: 1737-1747. doi: 10.2147/IJN.S29376.
122. Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR. 2006. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. Cancer Ther. 5(12): 3162-3169.
123. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE. 2005. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther. 12(21): 1544-1550.
124. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, Link MP. 2002. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin. Cancer Res. 8(2): 413-418.
125. Maul T, Bargiela A, Yan Y, Gao N, Foss A. 2013. Simulation modelling study of self-assembled nanoparticle coatings for retinal implants. J. Bionic Eng. 10: 65-76. doi: 10.1016/S1672-6529(13)60200-0.
126. McBride DW, Hsu MS, Rodgers VG, Binder DK. 2012. Improved survival following cerebral edema using a novel hollow fiber-hydrogel device. J. Neurosurg. 116(6): 1389-1394. doi: 10.3171/2012.2.JNS111540.
127. McKeran RO, Firth G, Oliver S, Uttley D, O'Laoire S. 1985. A potential application for the intracerebral injection of drugs entrapped within liposomes in the treatment of human cerebral gliomas. J. Neurol. Neurosurg. Psychiatry 48(12): 1213-1219.
128. Medberry CJ, Crapo PM, Siu BF, Carruthers CA, Wolf MT, Nagarkar SP, Agrawal V, Jones KE, Kelly J, Johnson SA, Velankar SS, Watkins SC, Modo M, Badylak SF. 2013. Hydrogels derived from central nervous system extracellular matrix. Biomaterials 34(4): 1033-1040. doi: 10.1016/j.biomaterials.2012.10.062.
129. Merodio M, Irache JM, Valamanesh F, Mirshahi M. 2002. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 23(7): 1587-1594.
130. Millward JM, Schnorr J, Taupitz M, Wagner S, Wuerfeld JT, Infante-Duarte C. 2013. Iron oxide magnetic nanoparticles highlight early involvement of the choroid plexus in central nervous system inflammation. ASN Neuro 5(2): e00110. doi: 10.1042/AN20120081.
131. Mohtaram NK, Montgomery A,Willerth SM. 2013. Biomaterialbased drug delivery systems for the controlled release of neurotrophic factors. Biomed. Mater. 8(2): 022001. doi: 10.1088/1748-6041/8/2/022001.
132. Molinari A, Bombelli C, Mannino S, Stringaro A, Toccacieli L, Calcabrini A, Colone M, Mangiola A, Maira G, Luciani P, Mancini G, Arancia G. 2007. m-THPC-mediated photodynamic therapy of malignant gliomas: assessment of a new transfection strategy. Int. J. Cancer 121(5): 1149-1155.
133. Molnár PP, O'Neill BP, Scheithauer BW, Groothuis DR. 1999. The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death. NeuroOncol. 1(2): 89-100.
134. Nair M, Guduru R, Liang P, Hong J, Sagar V, Khizroev S. 2012. Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat. Commun. 4: 1707-1714. doi: 10.1038/ncomms2717.
135. Nakamura H. 2009. Liposomal boron delivery for neutron capture therapy. Methods Enzymol. 465: 179-208. doi: 10.1016/S0076-6879(09)65010-2.
136. Navajas A, Lassaletta A, Morales A, López-Ibor B, Sábado C, Moscardó C, Mateos E, Molina J, Sagaseta M, Sastre A. 2012. Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement. Clin. Transl. Oncol. 14(4): 280-286. doi: 10.1007/s12094-012-0796-0.
137. Neuwelt EA, Várallyay P, Bagó AG, Muldoon LL, Nesbit G, Nixon R. 2004. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol. Appl. Neurobiol. 30(5): 456-471.
138. Nico B, Ribatti D. 2012. Morphofunctional aspects of the blood-brain barrier. Curr. Drug Metab. 13: 50-60.
139. Nicolas G, Pottier C, Maltête D, Coutant S, Rovelet-Lecrux A, Legallic S, Rousseau S, Vaschalde Y, Guyant-Maréchal L, Augustin J, Martinaud O, Defebvre L, Krystkowiak P, Pariente J, Clanet M, Labauge P, Ayrignac X, Lefaucheur R, Le Ber I, Frébourg T, Hannequin D, Campion D. 2013. Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology 80: 181-187. doi: 10.1212/WNL.0b013e31827ccf34.
140. Nie G, Hah HJ, Kim G, Lee YE, Qin M, Ratani TS, Fotiadis P, Miller A, Kochi A, Gao D, Chen T, Orringer DA, Sagher O, Philbert MA, Kopelman R. 2012. Hydrogel nanoparticles with covalently linked coomassie blue for brain tumor delineation visible to the surgeon. Small 8(6): 884-891. doi: 10.1002/smll.201101607.
141. Nisbet DR, Rodda AE, Horne MK, Forsythe JS, Finkelstein DI. 2010. Implantation of functionalized thermally gelling xyloglucan hydrogel within the brain: associated neurite infiltration and inflammatory response. Tissue Eng. Part A 16(9): 2833-2842. doi: 10.1089/ten.TEA.2009.0677.
142. Osanai T, Kuroda S, Yasuda H, Chiba Y, Maruichi K, Hokari M, Sugiyama T, Shichinohe H, Iwasaki Y. 2010. Noninvasive transplantation of bone marrow stromal cells for ischemic stroke: preliminary study with a thermoreversible gelation polymer hydrogel. Neurosurgery 66(6): 1140-1147. doi: 10.1227/01.NEU.0000369610.76181.CF.
143. Osbun JW, Ellenbogen RG, Chesnut RM, Chin LS, Connolly PJ, Cosgrove GR, Delashaw JB, Jr, Golfinos JG, Greenlee JD, Haines SJ, Jallo J, Muizelaar JP, Nanda A, Shaffrey M, Shah MV, Tew JM, Jr, van Loveren HR, Weinand ME, White JA, Wilberger JE. 2012. A multicenter, single-blind, prospective randomized trial to evaluate the safety of a polyethylene glycol hydrogel (Duraseal Dural Sealant System) as a dural sealant in cranial surgery. World Neurosurg. 78(5): 498-504. doi: 10.1016/j.wneu.2011.12.011.
144. Ozeki T, Kaneko D, Hashizawa K, Imai Y, Tagami T, Okada H. 2012a. Combination therapy of surgical tumor resection with implantation of a hydrogel containing camptothecin-loaded poly(lactic-co-glycolic acid) microspheres in a C6 rat glioma model. Biol. Pharm. Bull. 35(4): 545-550.
145. Ozeki T, Kaneko D, Hashizawa K, Imai Y, Tagami T, Okada H. 2012b. Improvement of survival in C6 rat glioma model by a sustained drug release from localized PLGA microspheres in a thermoreversible hydrogel. Int. J. Pharmacol. 427(2): 299-304. doi: 10.1016/j.ijpharm.2012.02.012.
146. Park K, Chen Y, Hu Y, Mayo AS, Kompella UB, Longeras R, Ma JX. 2009. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 58(8): 1902-1913. doi: 10.2337/db08-1327.
147. Park J, Lim E, Back S, Na H, Park Y, Sun K. 2010. Nerve regeneration following spinal cord injury using matrix metalloproteinase-sensitive, hyaluronic acid-based biomimetic hydrogel scaffold containing brain-derived neurotrophic factor. J. Biomed. Mater. Res. A 93(3): 1091-1099. doi: 10.1002/jbm.a.32519.
148. Passarin MG, Moretto G, Musso AM, Ottaviani S, Masotto B, Ghimenton C, Iuzzolino P, Buffone E, Rudà R, Soffietti R, Vattemi E, Pedersini R. 2010. Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. J. Neurooncol. 97(3): 439-444. doi: 10.1007/s11060-009-0040-0.
149. Percy DB, Ribot EJ, Chen Y, McFadden C, Simedrea C, Steeg PS, Chambers AF, Foster PJ. 2011. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest. Radiol. 46(11): 718-725. doi: 10.1097/RLI.0b013e318226c427.
150. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13): 1605-1612. doi: 10.1002/jcc.20084.
151. Peyrl A, Sauermann R, Traunmueller F, Azizi AA, Gruber-Olipitz M, Gupper A, Slavc I. 2009. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Clin. Pharmacokinet. 48(4): 265-271. doi: 10.2165/00003088-200948040-00004.
152. Pickett GE, Laitt RD, Herwadkar A, Hughes DG. 2007. Visual pathway compromise after hydrocoil treatment of large ophthalmic aneurysms. Neurosurgery 61(4): E873-E874.
153. Pollinger K, Hennig R, Ohlmann A, Fuchshofer R, Wenzel R, Breunig M, Tessmar J, Tamm ER, Goepferich A. 2013. Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application. Proc. Natl. Acad. Sci. U. S. A. 110(15): 6115-6120. doi: 10.1073/pnas.1220281110.
154. Previtera ML, Langhammer CG, Langrana NA, Firestein BL. 2010. Regulation of dendrite arborization by substrate stiffness is mediated by glutamate receptors. Ann. Biomed. Eng. 38(12): 3733-3743. doi: 10.1007/s10439-010-0112-5.
155. Prow TW, Bhutto I, Kim SY, Grebe R, Merges C, McLeod DS, Uno K, Mennon M, Rodriguez L, Leong K, Lutty GA. 2008. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 4(4): 340-349. doi: 10.1016/j.nano.2008.06.003.
156. Qiao R, Jia Q, Hüwel S, Xia R, Liu T, Gao F, Galla H-J, Gao M. 2012. Receptor-mediated delivery of magnetic nanoparticles across the blood brain barrier. ACS Nano 6(4): 3304-3310. doi: 10.1021/nn300240p.
157. Ranganath SH, Kee I, Krantz WB, Chow PK, Wang CH. 2009. Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy. Pharm. Res. 26(9): 2101-2114. doi: 10.1007/s11095-009-9922-2.
158. Redzic Z. 2011. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barr. CNS 8(1): 3. doi: 10.1186/2045-8118-8-3.
159. Saik JE, Gould DJ, Keswani AH, Dickinson ME, West JL. 2011. Biomimetic hydrogels with immobilized ephrinA1 for therapeutic angiogenesis. Biomacromolecules 12(7): 2715-2722. doi: 10.1021/bm200492h.
160. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. 2004. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 64(7): 2572-2579.
161. Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS. 2006. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol. 8(3): 205-214.
162. Sakai T, Kohno H, Ishihara T, Higaki M, Saito S, Matsushima M, Mizushima Y, Kitahara K. 2006. Treatment of experimental autoimmune uveoretinitis with poly(lacticacid) nanoparticles encapsulating betamethasone phosphate. Exp. Eye Res. 82(4): 657-663.
163. Sanders K, Degn LL, Mundy WR, Zucker RM, Dreher K, Zhao B, Roberts JE, Boyes WK. 2012. In vitro phototoxicity and hazard identification of nano-scale titanium dioxide. Toxicol. Appl. Pharmacol. 258(2): 226-236. doi: 10.1016/j.taap.2011.10.023.
164. Sarin H, Kanevsky AS,Wu H, Brimacombe KR, Fung SH, Sousa AA, Auh S, Wilson CM, Sharma K, Aronova MA, Leapman RD, Griffiths GL, Hall MD. 2008. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Transl. Med. 6: 80. doi: 10.1186/1479-5876-6-80.
165. Sarin H, Kanevsky AS, Wu H, Sousa AA, Wilson CM, Aronova MA, Griffiths GL, Leapman RD, Vo HQ. 2009. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J. Transl. Med. 7: 51. doi: 10.1186/1479-5876-7-51.
166. Saunders NR, Liddelowand SA, Dziegielewska KM. 2012. Barrier mechanisms in the developing brain. Front. Pharmacol. 3: 46. doi: 10.3389/fphar.2012.00046.
167. Schackert G, Fan D, Nayar R, Fidler IJ. 1989. Arrest and retention of multilamellar liposomes in the brain of normal mice or mice bearing experimental brain metastases. Sel. Cancer Ther. 5(2): 73-79.
168. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH,Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77(4): 491-502.
169. Schlosshauer B. 2007. Blood-retina barriers. In Handbook of Neurochemistry and Molecular Neurobiology. Neural Membrane and Transport, Lajtha A, Reith MAE (eds). Springer Science+Business Media, LLC: Berlin; 486-506. doi: 10.1007/978-0-387-30380-2_24.
170. Schönegger K, Gelpi E, Prayer D, Dieckmann K, Matula C, Hassler M, Hainfellner JA, Marosi C. 2005. Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anticancer Drugs 16(10): 1139-1143.
171. Schwonzen M, Kurbacher CM, Mallmann P. 2000. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 11(9): 681-685.
172. Seidlits SK, Khaing ZZ, Petersen RR, Nickels JD, Vanscoy JE, Shear JB, Schmidt CE. 2010. The effects of hyaluronic acid hydrogels with tunable mechanical properties on neural progenitor cell differentiation. Biomaterials 31(14): 3930-3940. doi: 10.1016/j.biomaterials.2010.01.125.
173. Seif AE, Reilly AF, Rheingold SR. 2010. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature. J. Pediatr. Hematol. Oncol. 32(8): e349-e352. doi: 10.1097/MPH.0b013e3181ec0c25.
174. Sharma US, Sharma A, Chau RI, Straubinger RM. 1997. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm. Res. 14(8): 992-998.
175. Siegal T, Horowitz A, Gabizon A. 1995. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83(6): 1029-1037.
176. Siegenthaler JA, Pleasure SJ. 2011. We have got you 'covered': how the meninges control brain development. Curr. Opin. Genet. Dev. 21(3): 249-255.
177. Silva NA, Cooke MJ, Tam RY, Sousa N, Salgado AJ, Reis RL, Shoichet MS. 2012. The effects of peptide modified gellan gum and olfactory ensheathing glia cells on neural stem/progenitor cell fate. Biomaterials 33(27): 6345-6354. doi: 10.1016/j.biomaterials.2012.05.050.
178. Sim SY, Shin YS, Yoon SH. 2008. Endovascular internal trapping of traumatic pericallosal pseudoaneurysm with hydrogel-coated self-expandable coil in a child: a case report. Surg. Neurol. 69(4): 418-422. doi: 10.1016/j.surneu.2007.02.042.
179. Skoza F, Papahadjopoulos D. 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. U. S. A. 75(9): 4194-4198.
180. Sodha S, Wall K, Redenti S, Klassen H, Young MJ, Tao SL. 2011. Microfabrication of a three-dimensional polycaprolactone thin-film scaffold for retinal progenitor cell encapsulation. J. Biomater. Sci. Polym. Ed. 22(4-6): 443-456. doi: 10.1163/092050610X487738.
181. Song B, Song J, Zhang S, Anderson MA, Ao Y, Yang CY, Deming TJ, Sofroniew MV. 2012. Sustained local delivery of bioactive nerve growth factor in the central nervous system via tunable diblock copolypeptide hydrogel depots. Biomaterials 33(35): 9105-9116. doi: 10.1016/j.biomaterials.2012.08.060.
182. Steuer H, Jaworski A, Elger B, Kaussmann M, Keldenich J, Schneider H, Stoll D, Schlosshauer B. 2005. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest. Ophthalmol. Vis. Sci. 46(3): 1047-1053.
183. Stolp H, Neuhaus A, Sundramoorthi R, Molnár Z. 2012. The long and the short of it: gene and environment interactions during early cortical development and consequences for long-term neurological disease. Front. Psychiat. 3: 50. doi: 10.3389/fpsyt.2012.00050.
184. Sun H, Dai H, Shaik N, Elmquist WF. 2003. Drug efflux transporters in the CNS. Adverse Drug Deliv. Rev. 55(1): 83-105. doi: 10.1016/S0169-409X(02)00172-2.
185. Suri S, Schmidt CE. 2010. Cell-laden hydrogel constructs of hyaluronic acid, collagen, and laminin for neural tissue engineering. Tissue Eng. Part A 16(5): 1703-1716. doi: 10.1089/ten.tea.2009.0381.
186. Tang R, Ji W, Panus D, Palumbo RN, Wang C. 2011. Block copolymer micelles with acid-labile ortho ester side-chains: Synthesis, characterization, and enhanced drug delivery to human glioma cells. J. Control. Release 151(1): 18-27. doi: 10.1016/j.jconrel.2010.12.005.
187. Tao Y, Ning M, Dou H. 2012. A novel therapeutic system for malignant glioma: nanoformulation, pharmacokinetic, and anticancer properties of cell-nano-drug delivery. Nanomed. Nanotech. Biol. Med., 9(2): 222-232. doi:10.1016/j.nano.2012.10.006.
188. Tong S, Cradick TJ, Ma Y, Dai Z, Bao G. 2012. Engineering imaging probes and molecular machines for nanomedicine. Sci. China Life Sci. 55(10): 843-861. doi: 10.1007/s11427-012-4380-1.
189. Torres AJ, Zhu C, Shuler ML, Pannullo S. 2011. Paclitaxel delivery to brain tumors from hydrogels: a computational study. Biotechnol. Prog. 27(5): 1478-1487. doi: 10.1002/btpr.665.
190. Tyler BM, Hdeib A, Caplan J, Legnani FG, Fowers KD, Brem H, Jallo G, Pradilla G. 2012. Delayed onset of paresis in rats with experimental intramedullary spinal cord gliosarcoma following intratumoral administration of the paclitaxel delivery system OncoGel. J. Neurosurg. Spine 16(1): 93-101. doi: 10.3171/2011.9.SPINE11435.
191. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, Petrillo A, Rink D, Neuwelt EA. 2002. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am. J. Neuroradiol. 23(4): 510-519.
192. Vellimana AK, Recinos VR, Hwang L, Fowers KD, Li KW, Zhang Y, Okonma S, Eberhart CG, Brem H, Tyler BM. 2013. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. J. Neurooncol. 111(3): 229-236. doi: 10.1007/s11060-012-1014-1.
193. Wadghiri YZ, Li J, Wang J, Hoang DM, Sun Y, Xu H, Tsui W, Li Y, Boutajangout A, Wang A, de Leon M, Wisniewski T. 2013. Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. PLoS One 8(2): e57097. doi: 10.1371/journal.pone.0057097.
194. Wagner S, Peters O, Fels C, Janssen G, Liebeskind AK, Sauerbrey A, Suttorp M, Hau P, Wolff JE. 2008. Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J. Neurooncol. 86(2): 175-181.
195. Wanakule P, Roy K. 2012. Disease-responsive drug delivery: the next generation of smart delivery devices. Curr. Drug Metab. 13(1): 42-49. doi: 10.2174/138920012798356880.
196. Wang H, Su W,Wang S,Wang X, Liao Z, Kang C, Han L, Chang J, Wang G, Pu P. 2012a. Smart multifunctional core-shell nanospheres with drug and gene co-loaded for enhancing the therapeutic effect in a rat intracranial tumor model. Nanoscale 4(20): 6501-6508.
197. Wang Y, Cooke MJ, Morshead CM, Shoichet MS. 2012b. Hydrogel delivery of erythropoietin to the brain for endogenous stem cell stimulation after stroke injury. Biomaterials 33(9): 2681-2692. doi: 10.1016/j.biomaterials.2011.12.031.
198. Wielgus AR, Zhao B, Chignell CF, Hu DN, Roberts JE. 2010. Phototoxicity and cytotoxicity of fullerol in human retinal pigment epithelial cells. Toxicol. Appl. Pharmacol. 242(1): 79-90. doi: 10.1016/j.taap.2009.09.021.
199. Wong LL, Hirst SM, Pye QN, Reilly CM, Seal S, McGinnis JF. 2013. Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection. PLoS One 8(3): e58431. doi: 10.1371/journal.pone.0058431.
200. Yamamoto S, Manabe N, Fujioka K, Hoshino A, Yamamoto K. 2007. Visualizing vitreous using quantum dots as imaging agents. IEEE Transl. Nanobiosci. 6(1): 94-98.
201. Yanagië H, Ogata A, Sugiyama H, Eriguchi M, Takamoto S, Takahashi H. 2008. Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin. Drug Deliv. 5(4): 427-443. doi: 10.1517/17425247.5.4.427.
202. Yim YS, Choi J, Kim GT, Kim CH, Shin T-H, Kim DG, Cheon J. 2012. A facile approach for the delivery of inorganic nanoparticles into the brain by passing through the blood-brain barrier (BBB). Chem. Commun. (Camb.) 48: 61-63. doi: 10.1039/c1cc15113d.
203. Yoshida J, Mizuno M. 2003. Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma. J. Neurooncol. 65(3): 261-267.
204. Yoshida J, Mizuno M, Fujii M, Kajita Y, Nakahara N, Hatano M, Saito R, Nobayashi M,Wakabayashi T. 2004. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum. Gene Ther. 15(1): 77-86.
205. Zhang D, Tian A, Xue X, Wang M, Qiu B, Wu A. 2012. The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior. Int J Mol Sci. 13(1): 1109-1125. doi:10.3390/ijms13011109.
206. Zhong J, Chan A, Morad L, Kornblum HI, Fan G, Carmichael ST. 2010. Hydrogel matrix to support stem cell survival after brain transplantation in stroke. Neurorehabil. Neural Repair 24(7): 636-644. doi: 10.1177/1545968310361958.
207. Zhou Z, Yu P, Geller HM, Ober CK. 2012. The role of hydrogels with tethered acetylcholine functionality on the adhesion and viability of hippocampal neurons and glial cells. Biomaterials 33(8): 2473-2481. doi: 10.1016/j.biomaterials.2011.12.005.
208. Zucchetti M, Boiardi A, Silvani A, Parisi I, Piccolrovazzi S, D'Incalci M. 1999. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother. Pharmacol. 44(2): 173-176.
209. Zuidema JM, Pap MM, Jaroch DB, Morrison FA, Gilbert RJ. 2011. Fabrication and characterization of tunable polysaccharide hydrogel blends for neural repair. Acta Biomater. 7(4): 1634-1643. doi: 10.1016/j.actbio.2010.11.039.
210. ClinicalTrials.gov http://www.clinicaltrials.gov/